Acta Scientific Medical Sciences (ISSN: 2582-0931)

Research ArticleVolume 5 Issue 4

Effect of Lipid Profile and Serum Creatinine on Hearing Loss in Diabetics

Muthumagesh Arunachalam1, BP Belaldavar2 and Rajesh Radhakrishna Havaldar3*

1Assistant Professor, Department of ENT, Thanjavur Medical College, Thanjavur, Tamilnadu, India
2DLO, International Fellowship in Rhinoplasty, Professor, Department of ENT and Head and Neck Surgery, KAHER’s JN Medical College, Belagavi, Karnataka, India and College of Medicine, Shaqra University, KSA
3Senior Resident, Department of ENT and Head and Neck Surgery, JN Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India

*Corresponding Author: Rajesh Radhakrishna Havaldar, Senior Resident, Department of ENT and Head and Neck Surgery, JN Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India.

Received: April 15, 2021; Published: May 06, 2021

Citation: Rajesh Radhakrishna Havaldar., et al. “Effect of Lipid Profile and Serum Creatinine on Hearing Loss in Diabetics". Acta Scientific Microbiology 5.6 (2021): 20-27.

Abstract

This article addresses important issues regarding the use of certain MRI contrast agents (linear and macrocylic gadolinium-based, non-gadolinium-based, iron-based, others). Specific attention is devoted to their corresponding safety and efficacy, and to their use or repeated use in patients with certain medical conditions.

 

Keywords: Imaging Agents; Linear Gadolinium-based; Macrocyclic Gadolinium-based; Non-gadolinium Based; Iron-based; Safety; Efficacy

Bibliography

  1. Centers for Disease Control and Prevention (CDC). "Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents". Morbidity and Mortality Weekly Report 56.7 (2007): 137-141.
  2. "EMA recommendations on Gadolinium-containing contrast agents". ema.europa.eu. Retrieved 2018-07-12. "Information on Gadolinium-Containing Contrast Agents". Fda.gov.
  3. "FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings" (PDF). United States Food and Drug Administration. 2017-12-19.
  4. Fymat AL. “Magnetic Resonance Imaging with Nanocontrasting Materials”, Invited Address presented at the BIT's 4th Annual Congress in Nanomedicine, Shuzou, China, June 2013 (2013).
  5. “Magnetic Resonance Imaging Modalities with Nanocontrasting Materials”. Journal of Current Trends in Clinical and Medical Imaging 1.1 (2017): 1-4.
  6. Geraldes CFGC and Laurent S. "Classification and basic properties of contrast agents for magnetic resonance imaging". Contrast Media and Molecular Imaging1 (2009): 1-23.
  7. Grobner T. "Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?". Nephrology Dialysis Transplantation4 (2005): 1104-1108.
  8. Kanal E., et al. "ACR Guidance Document for Safe MR Practices: 2007". American Journal of Roentgenology6 (2007): 1447-1474.
  9. Koretsky Alan P and Silva Afonso C. “"Manganese-enhanced magnetic resonance imaging (MEMRI)". NMR in Biomedicine8 (2004): 527-531.
  10. Marckmann P., et al. "Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging". Journal of the American Society of Nephrology9 (2006): 2359-2362.
  11. Murphy KJ., et al. "Adverse reactions to gadolinium contrast media: A 1996 review of 36 cases". American Journal of Roentgenology4 (1996): 847-849.
  12. Qiao Jingjuan., et al. "Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents". Journal of Biological Inorganic Chemistry2 (2014): 259-270.
  13. Rinck PA. "Chapter 13 - Contrast Agents". Magnetic Resonance in Medicine (11th ed.). European Magnetic Resonance Forum. Retrieved 2020-07-31 (2017).
  14. Sudarshana DM., et al. "Manganese-Enhanced MRI of the Brain in Healthy Volunteers". American Journal of Neuroradiology8 (2019): 1309-1316.
  15. Xue Shenghui., et al. "Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers". Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology2 (2013): 163-179.
  16. Xue Shenghui., et al. "Design of ProCAs (Protein-Based Gd3+ MRI Contrast Agents) with High Dose Efficiency and Capability for Molecular Imaging of Cancer Biomarkers". Medicinal Research Reviews5 (2014): 1070-1099.
  17. Zhen Zipeng and Xie J . "Development of Manganese-Based Nanoparticles as Contrast Probes for Magnetic Resonance Imaging". Theranostics 1 (2012): 45-54.

Copyright: © 2021 Alain L Fymat. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is September 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US